Deals In Depth: May 2018
In a $969 million deal, Genentech is investing in Lodo Therapeutics’ soil microbiome research to discover natural products. After several offers, Shire agreed a $79 billion takeover by Takeda, which moves into the top 10 pharma companies. Biopharma financing was slightly down while device financing increased, with a large proportion coming from FOPOs.
You may also be interested in...
Coming year could feature first-time approvals in the EU for at least five gene therapies.
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.